- The company’s MRIdian offers more accurate radiotherapy for cancer patients but they won’t have the field to themselves.
- Worries about the viability of the MRIdian are unfounded as a competitor takes a financial stake in the company.
- However, the case for investors is far from clear cut as order growth slows and losses, cash bleed, and dilution mount so we’ll pass on this one.
ViewRay’s MRIdian Is Promising, But Losses Mount
January 29th, 2020 · No Comments